Novel PSMA-Targeting Radionuclide Peptidomimetics for Treating Prostate Cancer

Page view(s)
49
Checked on Nov 08, 2024
Novel PSMA-Targeting Radionuclide Peptidomimetics for Treating Prostate Cancer
Title:
Novel PSMA-Targeting Radionuclide Peptidomimetics for Treating Prostate Cancer
Journal Title:
ACS Medicinal Chemistry Letters
Publication Date:
23 December 2022
Citation:
Chia, C. S. B. (2022). Novel PSMA-Targeting Radionuclide Peptidomimetics for Treating Prostate Cancer. ACS Medicinal Chemistry Letters, 14(1), 3–4. https://doi.org/10.1021/acsmedchemlett.2c00510
Abstract:
Prostate cancer is the third-most commonly diagnosed cancer and is one of the leading causes of cancer-related deaths in men worldwide. Although an armamentarium of approved drugs exists, treatment options become severely limited when resistance develops against last-line taxane chemotherapeutics. In March 2022, the FDA approved a first-in-class targeted radionuclide therapy, lutetium Lu 177 vipivotide tetraxetan (Pluvicto), for treating metastatic castration-resistant prostate cancer. The drug constitutes a prostate-specific membrane antigen-targeting peptidomimetic moiety conjugated to a radionuclide chelator via a linker. This Patent Highlight reveals the structure–activity relationship of key compounds against prostate cancer cells.
License type:
Publisher Copyright
Funding Info:
This research is supported by core funding from: Experimental Drug Development Centre (EDDC)
Grant Reference no. : N. A.
Description:
This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Medicinal Chemistry Letters, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see doi.org/10.1021/acsmedchemlett.2c00510
ISSN:
1948-5875
Files uploaded: